Suven Life Sciences up 9% on product patent from US

Suven Life Sciences is trading up 9% at Rs 33 levels after the company secured its fifth product patent from US patent office for their New Chemical Entity (NCE) to treat Central Nervous System (CNS) disorders.
 
“The granted claims of the patent include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia” the company said in a release to the BSE.
 
With this new patent, the company has a total five granted US product patent for their NCEs in CNS therapy.
 
The stock opened at Rs 31 and touched high of Rs 33 in intraday deals. The counter has seen robust volumes with 1.45 million shares changing hands so far on the BSE, as compared to an average 363,000 shares were traded in last two weeks.